Envista Holdings Corporation (NVST) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $25.82, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (53.0%); Analyst target reached - limited upside remaining.
Envista Holdings is a global dental products company with over 30 brands (Nobel Biocare, Ormco, Kerr) generating $2.7B in 2025 revenue across Specialty Products & Technologies (64%) and Equipment & Consumables (36%) segments. It sells primarily to dentists, oral surgeons, and... Read more
Hold if already holding. Not a fresh buy at $25.82, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (53.0%); Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.5/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news boost analyst 0.50, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational (outside U.S.)53%10-K Item 1A: 'In 2025, 53% of our sales were derived from customers outside the U.S.'
- LOWGeographicChina7.0%10-K Item 1A: 'we generate approximately 7% of our annual sales from China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $25.82, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside U.S.) (53.0%); Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $27.96 (+8.3%), stop $24.12 (−7.0%), A.R:R -0.5:1. Score 5.5/10, moderate confidence.
Take-profit target: $27.96 (+8.2% upside). Target $27.96 (+8.3%), stop $24.12 (−7.0%), A.R:R -0.5:1. Stop-loss: $24.12.
Concentration risk — Geographic: international (outside U.S.) (53.0%); Analyst target reached - limited upside remaining; Earnings in 6 days (event risk).
Envista Holdings Corporation trades at a P/E of 92.5 (forward 16.6). TrendMatrix value score: 6.2/10. Verdict: Hold.
20 analysts cover NVST with a consensus score of 4.0/5. Average price target: $29.
What does Envista Holdings Corporation do?Envista Holdings is a global dental products company with over 30 brands (Nobel Biocare, Ormco, Kerr) generating $2.7B...
Envista Holdings is a global dental products company with over 30 brands (Nobel Biocare, Ormco, Kerr) generating $2.7B in 2025 revenue across Specialty Products & Technologies (64%) and Equipment & Consumables (36%) segments. It sells primarily to dentists, oral surgeons, and orthodontists in 130+ countries, with ~53% of sales outside the U.S.